159 related articles for article (PubMed ID: 28397291)
1. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells.
Dash TK; Konkimalla VSB
J Pharm Pharmacol; 2017 Jul; 69(7):834-843. PubMed ID: 28397291
[TBL] [Abstract][Full Text] [Related]
2. Comparative Study of Different Nano-Formulations of Curcumin for Reversal of Doxorubicin Resistance in K562R Cells.
Dash TK; Konkimalla VB
Pharm Res; 2017 Feb; 34(2):279-289. PubMed ID: 27815791
[TBL] [Abstract][Full Text] [Related]
3. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
4. Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.
Dash TK; Konkimalla VB
Pharm Res; 2017 Aug; 34(8):1741-1750. PubMed ID: 28536971
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
6. Formulation and Optimization of Doxorubicin and Biochanin A Combinational Liposomes for Reversal of Chemoresistance.
Dash TK; Konkimalla VB
AAPS PharmSciTech; 2017 May; 18(4):1116-1124. PubMed ID: 27600324
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
Tam YT; To KK; Chow AH
Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance reversal by combretastatin-A4 phosphate loaded with doxorubicin in polymersomes independent of angiogenesis effect.
Zhu J; Hu M; Qiu L
J Pharm Pharmacol; 2017 Jul; 69(7):844-855. PubMed ID: 28425588
[TBL] [Abstract][Full Text] [Related]
10. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
12. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
[TBL] [Abstract][Full Text] [Related]
13. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.
Pramanik D; Campbell NR; Das S; Gupta S; Chenna V; Bisht S; Sysa-Shah P; Bedja D; Karikari C; Steenbergen C; Gabrielson KL; Maitra A; Maitra A
Oncotarget; 2012 Jun; 3(6):640-50. PubMed ID: 22791660
[TBL] [Abstract][Full Text] [Related]
14. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
16. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
17. DOX-loaded PEG-PLGA and Pluronic copolymer composite micelles enhances cytotoxicity and the intracellular accumulation of drug in DOX-resistant tumor cells.
Diao YY; Han M; Ding PT; Chen DW; Gao JQ
Pharmazie; 2010 May; 65(5):356-8. PubMed ID: 20503928
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines.
Chen L; Alrbyawi H; Poudel I; Arnold RD; Babu RJ
AAPS PharmSciTech; 2019 Feb; 20(3):99. PubMed ID: 30719596
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation and release of the hypnotic agent zolpidem from biodegradable polymer microparticles containing hydroxypropyl-beta-cyclodextrin.
Trapani G; Lopedota A; Boghetich G; Latrofa A; Franco M; Sanna E; Liso G
Int J Pharm; 2003 Dec; 268(1-2):47-57. PubMed ID: 14643976
[TBL] [Abstract][Full Text] [Related]
20. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
